圣诺生物(688117) - 2025 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2025 reached RMB 741.34 million, an increase of 62.55% compared to the previous year[3] - The net profit attributable to the parent company was RMB 165.82 million, reflecting a growth of 231.49% year-over-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 172.65 million, up 278.52% from the previous year[3] - The basic earnings per share increased to RMB 1.05, a rise of 133.33% compared to the previous year[3] Assets and Equity - Total assets at the end of 2025 amounted to RMB 1,937.13 million, representing a growth of 17.55% from the beginning of the year[4] - The equity attributable to the parent company was RMB 1,065.50 million, an increase of 16.02% from the beginning of the year[4] Business Development - The company focused on the synergistic development of peptide drug CDMO, raw materials, and formulations, leading to a significant increase in sales of GLP-1 raw materials[7] - The increase in operating revenue and net profit was primarily driven by the expansion of domestic and international markets for raw materials, particularly for semaglutide and teriparatide[9] Share Capital - The company's share capital increased by 40% due to a capital reserve conversion, raising the total shares from 112,418,556 to 157,385,978[9] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[10]